“Dramatic” Responses with Targeted Agent for Patients with CLL

A 22-month survival in 96% of treatment-naïve patients
February 2013 Vol 6, No 1, Special Issue - Leukemia
Charles Bankhead

Atlanta, GA—Targeting Bruton’s tyrosine kinase (BTK) in patients with chronic lymphocytic leukemia (CLL) resulted in high response rates, without severe toxicity, according to the results of 2 studies that were presented at the 2012 ASH meeting.

Data from one trial showed a 70% response rate in 116 patients treated with ibrutinib and a 22-month survival of 96% in previously untreated patients and 76% in the subgroup with relapsed/refractory CLL.

A second study reported at the meeting demonstrated objective responses in 83% of patients with high-risk CLL who were treated with ibrutinib.

“Ibrutinib has the potential to change the treatment landscape in CLL,” said John C. Byrd, MD, Director of Hematology at The Ohio State University Comprehensive Cancer Center in Columbus during a press conference.

BTK has emerged as a key player in the abnormal B-cell antigen receptor signaling that drives CLL and certain other B-cell diseases. Ibrutinib is one of several BTK inhibitors in development and is the farthest along in clinical investigation.

Dr Byrd presented results from a trial of ibrutinib monotherapy involving 85 patients with previously treated CLL and 31 treatment-naïve patients. All patients received 420 mg daily orally, which was associated with a 68% objective response rate (10% complete response [CR]) in the previously untreated patients and 70% (2% CR) in the relapsed/refractory group. In addition, 13% of the treatment-naïve patients and 4% of patients in the relapsed/refractory group had stable disease.

At 22 months, 96% of the treated sub­­group remained alive, as did 85% of the patients with relapsed/refractory disease.

The second trial involved 40 patients with poor-prognosis CLL. The cohort included patients with a history of poor response to therapy and those with unfavorable genetics, said Jan Burger, MD, PhD, a hematologic oncologist at The University of Texas M.D. Anderson Cancer Center in Houston.

All patients received ibrutinib daily plus weekly infusions of rituximab during the first month, followed by once-monthly infusions thereafter. The regimen resulted in 1 CR, 32 partial responses, 2 minor responses, and no response in 2 patients. Two other patients had not been treated long enough for a response assessment.

Dr Burger characterized the ibrutinib- rituximab combination as highly active, not that several patients had particularly dramatic responses.
In both trials, ibrutinib was associated with low rates of severe toxicity. Dr Byrd reported a 13% incidence of grade 3/4 myelosuppression and grade 3/4 infection in 10% of untreated and 40% of relapsed/refractory patients.

Dr Burger reported 13 cases of grade 3/4 toxicity, including neutropenia, fatigue, pneumonia, insomnia, and bone pain.

Diarrhea was the most common adverse effect associated with ibrutinib in both trials, and cases were grade 1/2 in severity.

“Most side effects were modest and went away after the first couple of cycles of therapy,” noted Dr Byrd.

Related Items
First National Study: Geographic Socioeconomic Disparities Mirror Substantial Gaps in Survival in Children with AML
Chase Doyle
February 2020 Vol 13, Special Issue published on February 25, 2020 in Leukemia, Value-Based Care
Zanubrutinib, Next-Generation BTK, Leads to Impressive Responses in Patients with CLL or SLL
Phoebe Starr
February 2020 Vol 13, Special Issue published on February 25, 2020 in Leukemia
First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL
Wayne Kuznar
February 2020 Vol 13, Special Issue published on February 25, 2020 in Leukemia
Investigational Oral Form of Azacitidine Improves Survival Maintenance Therapy in Patients with Acute Myeloid Leukemia
Wayne Kuznar
February 2020 Vol 13, Special Issue published on February 25, 2020 in Leukemia
All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy
Wayne Kuznar
February 2020 Vol 13, Special Issue published on February 25, 2020 in Leukemia
Last modified: March 4, 2013
Copyright © Engage Healthcare Communications, LLC. All rights reserved.